Montaser Shaheen

7.5k total citations
60 papers, 1.5k citations indexed

About

Montaser Shaheen is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Montaser Shaheen has authored 60 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 24 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Montaser Shaheen's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (17 papers) and CAR-T cell therapy research (14 papers). Montaser Shaheen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (17 papers) and CAR-T cell therapy research (14 papers). Montaser Shaheen collaborates with scholars based in United States, France and Australia. Montaser Shaheen's co-authors include Robert Hromas, Jac A. Nickoloff, Elizabeth A. Williamson, Suk‐Hee Lee, Chris Allen, Anna C. Pavlick, Caroline Robert, Michael A. Postow, Justin Wray and Mario Sznol and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nucleic Acids Research.

In The Last Decade

Montaser Shaheen

58 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Montaser Shaheen United States	20	862	736	400	122	119	60	1.5k
Sriram Balasubramanian United States	21	754 0.9×	1.1k 1.5×	365 0.9×	126 1.0×	66 0.6×	61	2.0k
Csaba Mahotka Germany	22	517 0.6×	1.4k 1.9×	350 0.9×	139 1.1×	159 1.3×	46	1.7k
Tsuyoshi Takahashi Japan	16	421 0.5×	426 0.6×	340 0.8×	142 1.2×	63 0.5×	34	1.1k
Shu‐Fen Chiang Taiwan	26	694 0.8×	725 1.0×	504 1.3×	202 1.7×	219 1.8×	55	1.6k
Michael Wanzel Germany	16	578 0.7×	1.2k 1.7×	137 0.3×	73 0.6×	130 1.1×	25	1.7k
Carmela Gurrieri Italy	18	393 0.5×	915 1.2×	353 0.9×	91 0.7×	80 0.7×	46	1.5k
Wendy Béguelin United States	20	555 0.6×	763 1.0×	402 1.0×	83 0.7×	54 0.5×	34	1.4k
Jie Dai China	26	1.0k 1.2×	937 1.3×	394 1.0×	293 2.4×	91 0.8×	98	1.8k
Franz Kohlhuber Germany	15	825 1.0×	1.1k 1.5×	357 0.9×	70 0.6×	67 0.6×	17	1.8k
Van S. Tompkins United States	18	481 0.6×	724 1.0×	116 0.3×	44 0.4×	95 0.8×	35	1.1k

Countries citing papers authored by Montaser Shaheen

Since Specialization

Citations

This map shows the geographic impact of Montaser Shaheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Montaser Shaheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Montaser Shaheen more than expected).

Fields of papers citing papers by Montaser Shaheen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Montaser Shaheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Montaser Shaheen. The network helps show where Montaser Shaheen may publish in the future.

Co-authorship network of co-authors of Montaser Shaheen

This figure shows the co-authorship network connecting the top 25 collaborators of Montaser Shaheen. A scholar is included among the top collaborators of Montaser Shaheen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Montaser Shaheen. Montaser Shaheen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

George, Thomas J., Ji‐Hyun Lee, David L. DeRemer, et al.. (2024). Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. JCO Precision Oncology. 8(8). e2400406–e2400406. 6 indexed citations

Jaiswal, Aruna S., Arijit Dutta, Gayathri Srinivasan, et al.. (2023). TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells. Nucleic Acids Research. 51(22). 12224–12241. 10 indexed citations

Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2023). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical Cancer Research. 30(1). 74–81. 28 indexed citations

Shaheen, Montaser, Julie Y. Tse, Ethan Sokol, et al.. (2022). Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial. eLife. 11. 9 indexed citations

Amin, Asim, Mohammed Milhem, Georgina V. Long, et al.. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.. Journal of Clinical Oncology. 37(15_suppl). 9555–9555. 6 indexed citations

Carducci, Michael A., Montaser Shaheen, Ben Markman, et al.. (2018). A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. 36(6). 1060–1071. 33 indexed citations

Fisher, George A., Edward M. Wolin, Susan Pitman Lowenthal, et al.. (2018). Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-Reported Symptoms in Patients Responsive To Prior Octreotide Therapy And Patients Naïve To Somatostatin Analogue Therapy in The Elect Phase 3 Study. Endocrine Practice. 24(3). 243–255. 10 indexed citations

Long, Georgina V., Mohammed Milhem, A. Amin, et al.. (2018). Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of Oncology. 29. viii736–viii736. 4 indexed citations

Wolin, Edward M., George A. Fisher, Beloo Mirakhur, et al.. (2018). Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.. Journal of Clinical Oncology. 36(4_suppl). 347–347. 1 indexed citations

10.

Sznol, Mario, Michael A. Postow, Marianne Davies, et al.. (2017). Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews. 58. 70–76. 216 indexed citations

11.

Infante, Jeffrey R., Amita Patnaik, Claire F. Verschraegen, et al.. (2017). Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 79(2). 315–326. 29 indexed citations

12.

Kumar, Abhijeet, et al.. (2017). Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research. 123. 95–102. 52 indexed citations

13.

Wolin, Edward M., George A. Fisher, Pamela L. Kunz, et al.. (2016). Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study. Annals of Oncology. 27. vi143–vi143. 1 indexed citations

14.

Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2016). Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer. 4(1). 44–44. 51 indexed citations

15.

Zakharia, Yousef, Joseph J. Drabick, Samir N. Khleif, et al.. (2016). Abstract CT087: Phase II trial of theiIndoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus immune checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. Cancer Research. 76(14_Supplement). CT087–CT087. 3 indexed citations

16.

Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2015). A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).. Journal of Clinical Oncology. 33(15_suppl). 9032–9032. 6 indexed citations

17.

Rao, Arpit, et al.. (2015). Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction.. Journal of Clinical Oncology. 33(15_suppl). e14027–e14027. 1 indexed citations

18.

Williamson, Elizabeth A., Leah A. Damiani, Andrei Leitão, et al.. (2012). Targeting the Transposase Domain of the DNA Repair Component Metnase to Enhance Chemotherapy. Cancer Research. 72(23). 6200–6208. 30 indexed citations

19.

Wray, Justin, Elizabeth A. Williamson, Melanie Royce, et al.. (2009). Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells. PLoS ONE. 4(4). e5323–e5323. 43 indexed citations

20.

Shaheen, Montaser, et al.. (2004). Phase II Study of Ifosfamide Plus Daily Oral Etoposide in Previously Treated Ovarian Cancer. American Journal of Clinical Oncology. 27(3). 229–231. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact